SenesTech, Inc.(SNES)

$1.49—

Chart

SenesTech, Inc.(SNES)

NASDAQ

$1.49—

Chart Studio

SNES(SNES)

SNES

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/1/26

SENESTECH (SNES)

Wednesday

1:54 AM

Thesis: SenesTech: the story is balanced — New commercial customer wins or multi-year contract announcements with major pest management operators or municipal…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$2M	$2M	$4M
Rev. Growth	+19.6%	+5.7%	+91.2%
EPS	$-1.95	$-1.48	$-1.25
EPS Growth	+78.0%	+24.1%	+15.9%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $4M — +91.2% growth in a single year.

What Moves the Stock

1New commercial customer wins or multi-year contract announcements with major pest management operators or municipal accounts
2Quarterly product sales volume and revenue growth rates, particularly acceleration beyond current 56% YoY growth trajectory
3Regulatory developments including EPA label expansions, state-level approvals, or international registrations (EU, Asia-Pacific markets)
4Cash burn rate and runway updates given negative operating cash flow and small market cap requiring potential capital raises
5Peer-reviewed efficacy studies or field trial results demonstrating ROI metrics for commercial customers
6ContraPest product sales to commercial pest management operators and distributors (estimated 70-80% of revenue)
7Direct sales to municipal customers and agricultural facilities (estimated 15-25%)
8Potential licensing or partnership revenue from international markets (emerging)

FY2025 Snapshot

Revenue: $2M
Rev. Growth: +19.6%
Gross Margin: 62.5%
Op. Margin: -293%
Net Margin: -287%
Net Income: $-6M
NI Growth: -3.2%
EPS: $-1.95
1Y Return: -68.7%

My Notes

growth - The stock attracts speculative biotech investors focused on disruptive pest management technology with asymmetric upside if…
Rising rates create dual pressures: higher discount rates compress valuation multiples for pre-profitable biotech companies…
Watch on earnings: Quarterly ContraPest sales volume in gallons or units sold, tracking commercial adoption velocity, Customer concentration metrics and number of active commercial accounts to assess market penetration, Gross margin percentage trends indicating manufacturing scale efficiencies or raw material cost pressures.

One Sentence Summary:

SenesTech: the story is balanced — new commercial customer wins or multi-year contract announcements with major pest management operators or municipal accounts.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

P/E

—

What Moves the Stock

1New commercial customer wins or multi-year contract announcements with major pest management operators or municipal accounts

2Quarterly product sales volume and revenue growth rates, particularly acceleration beyond current 56% YoY growth trajectory

3Regulatory developments including EPA label expansions, state-level approvals, or international registrations (EU, Asia-Pacific markets)

4Cash burn rate and runway updates given negative operating cash flow and small market cap requiring potential capital raises

5Peer-reviewed efficacy studies or field trial results demonstrating ROI metrics for commercial customers

6ContraPest product sales to commercial pest management operators and distributors (estimated 70-80% of revenue)

7Direct sales to municipal customers and agricultural facilities (estimated 15-25%)

8Potential licensing or partnership revenue from international markets (emerging)

My Notes

growth - The stock attracts speculative biotech investors focused on disruptive pest management technology with asymmetric upside if…

Rising rates create dual pressures: higher discount rates compress valuation multiples for pre-profitable biotech companies…

Watch on earnings: Quarterly ContraPest sales volume in gallons or units sold, tracking commercial adoption velocity, Customer concentration metrics and number of active commercial accounts to assess market penetration, Gross margin percentage trends indicating manufacturing scale efficiencies or raw material cost pressures.

SENESTECH (SNES)

Revenue Outlook

What Moves the Stock

SNES Chart

My Notes

One Sentence Summary:

Explore More

SENESTECH (SNES)

Revenue Outlook

What Moves the Stock

SNES Chart

My Notes

One Sentence Summary: